These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 9215826)

  • 1. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ; Trump D
    J Clin Oncol; 1997 Jul; 15(7):2564-9. PubMed ID: 9215826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
    Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
    Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
    J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
    J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
    Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K; Watanabe H; Kobayashi T; Maegawa M
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.